News

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). The phase III programme includes two studies assessing the safety and efficacy of daprodustat compared to recombinant human erythropoietin.

This is the second and final study agreed with the U.S. Food and Drug Administration (FDA) to support the registration of liquid-frozen IMVAMUNE. The first study, a lot

The grant will fund a new clinical trial for Severe Combined Immunodeficiency caused by adenosine deaminase deficiency, commonly known as ADA-SCID or “bubble baby” disease. ADA-SCID is a

The requests raised by the FDA pertain only to Chemistry, Manufacturing and Controls (CMC). As the CRL did not cite efficacy or safety issues, Green Cross believes that

ORI Healthcare Fund (ORI Fund) led the Series C financing with participation by Shenzhen Hepalink Pharmaceutical (Hepalink). Existing shareholders Wellcome Trust, Bill & Melinda Gates Foundation, Malin Corporation,

Under the partnership, WuXi Biologics will be the exclusive clinical manufacturer for IMP321 for Prima worldwide, excluding any manufacturing for the supply of China, Macau, Taiwan and Hong

The clinical hold was initiated after two patients suffered cerebral edema earlier this week. One patient died and as of last night the other is not expected to

The collaboration follows the recent acquisition of the technology for the manufacture of IFNα by Neovacs from AMEGABIOTECH. This license agreement will allow Neovacs to directly transfer AMEGABIOTECH's

EGPA is a rare disease in which patients suffer from inflammation that is widespread in the walls of small blood vessels. The treatment aims is to induce and